Frontlight ResearchEarly access
CompletedPhase 3
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.
Key facts
- Who runs it
- Ionis Pharmaceuticals Inc.
- Where
- Bulgaria, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, and Sweden85 sites in 15 countriesChoose a country to see its sites
- Trial code
- 2021-002192-19
- 2024-510696-38-00
- NCT05681351
- U1111-1302-3919
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 368 people enrolled
- Started
- 8 Mar 2022
- Ended
- 28 May 2025
- Type of study
- Interventional
- Record updated
- 30 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
- Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study
- 18 Years and older (Adult, Older Adult)
Who cannot take part
- Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
- Total bilirubin > upper limit of normal unless due to Gilbert's syndrome
- Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal
This trial has no sites in United States.
It has sites in 15 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting TG from Baseline.
Data and sources
- Registry record
- How to verify a trial in the registry
- Official title
- ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
- Record updated
- 30 June 2025